Moderna stock: Phase 3 melanoma win with Merck — the numbers are not out yet
Aug. 19: Moderna and Merck said intismeran autogene plus Keytruda met Phase 3 melanoma endpoints. MRNA ripped on the headline; MRK rose too. Hazard ratios not disclosed — full data at a medical meeting.